Cagrilintide clinical trials
Also written NNC0174-0833.
ClinicalTrials.gov finds 45 studies for cagrilintide. How that becomes 50 here
Every study that search finds has been read, to see whether and how it gives cagrilintide. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 45Found by its intervention search · See all 45 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 41 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- +7Give it under a name that search misses: a biosimilar’s code or a misspelling
- 52Give cagrilintide to participants
- −1Compare another treatment with it
- −1Give it beside what is tested
- 50Test it: the count on this site
Get an email when these change. Save the cagrilintide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
50 studies that test it; most in 2026 (13)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 8 |
| 2024 | 12 |
| 2025 | 7 |
| 2026 | 13 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 50 · Other 0
Often tested with
Tested in the same studies.
Semaglutide (3) · Atorvastatin (1) · Warfarin (1) · Zalfermin (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
New treatments tested with it · 1 most studied
New when their studies opened, with cagrilintide beside them; studies of each.
Reaching primary completion within a year · 10, 6 in phase 3
Studies that test cagrilintide, phase 3 first.
- Mar 2027A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termPhase 3 · Novo Nordisk A/S
- May 2027Weight Loss in People Living With Overweight or Obesity Following Treatment With CagrilintidePhase 3 · Novo Nordisk A/S
- May 2027Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintidePhase 3 · Novo Nordisk A/S
- May 2027A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body WeightPhase 3 · Novo Nordisk A/S
- Jun 2027Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaPhase 3 · Novo Nordisk A/S
- Sep 2027REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsPhase 3 · Novo Nordisk A/S
- Apr 2027A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or ObesityPhase 1 · Novo Nordisk A/S
- May 2027A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or ObesityPhase 1 · Novo Nordisk A/S
- Oct 2027A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietPhase 1 · Novo Nordisk A/S
- Nov 2027Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse EventsPhase 1 · Novo Nordisk A/S
Studies
Open first, then newest update. How each study uses cagrilintide has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 50
- A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and ObesityNot yet recruitingPhase 3Novo Nordisk A/SNCT07919405CagriSema against each part and placebo on blood pressureWritten as CagriSemaReport a problem
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesRecruitingPhase 3Novo Nordisk A/SNCT07282613CagriSema against placebo in young people with type 2 diabetesWritten as CagriSema (Cagrilintide B and Semaglutide I)Report a problem
- Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse EventsRecruitingPhase 1Novo Nordisk A/SNCT07607587Against placebo in people who could not tolerate GLP-1 drugsWritten as CagrilintideReport a problem
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightRecruitingPhase 3Novo Nordisk A/SNCT07253285Alone or as CagriSema for weight loss in children and adolescentsWritten as CagrilintideReport a problem
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightRecruitingPhase 3Novo Nordisk A/SNCT07564414Two CagriSema doses against semaglutide for weight lossWritten as CagrisemaReport a problem
- Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaRecruitingPhase 3Novo Nordisk A/SNCT07817251Switching from semaglutide to CagriSema in type 2 diabetesWritten as CagriSemaReport a problem
- The Role of the Amylin Analogue Cagrilintide in Bone MetabolismRecruitingPhase 1Novo Nordisk A/SNCT07010432Alone, with semaglutide or as CagriSema on bone lossWritten as CagrilintideReport a problem
- A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body WeightRecruitingPhase 3Novo Nordisk A/SNCT07745504Two cagrilintide pen versions against placebo for weight lossWritten as CagrilintideReport a problem
- A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or ObesityRecruitingPhase 1Novo Nordisk A/SNCT07597018Bioequivalence of two cagrilintide versionsWritten as Cagrilintide DReport a problem
- A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or ObesityRecruitingPhase 1Novo Nordisk A/SNCT07557953Its effect on food intake and appetiteWritten as CagrilintideReport a problem
- Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)RecruitingPhase 1Novo Nordisk A/SNCT07527195Alone, with semaglutide or as CagriSema on muscle healthWritten as CagrilintideReport a problem
- Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideActive, not recruitingPhase 3Novo Nordisk A/SNCT07220759Alone against placebo for weight loss in type 2 diabetesWritten as CagrilintideReport a problem
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorCompletedPhase 3Novo Nordisk A/SNCT06221969CagriSema against tirzepatide in type 2 diabetes on metforminWritten as CagrilintideReport a problem
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothCompletedPhase 3Novo Nordisk A/SNCT06534411Low-dose CagriSema against tirzepatide in type 2 diabetesWritten as CagrilintideReport a problem
- A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightActive, not recruitingPhase 3Novo Nordisk A/SNCT05567796CagriSema against each part and placebo for weight lossWritten as CagrilintideReport a problem
- A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termActive, not recruitingPhase 3Novo Nordisk A/SNCT07011667CagriSema for weight loss and long-term maintenanceWritten as CagriSema (Cagrilintide B and Semaglutide I)Report a problem
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseCompletedPhase 3Novo Nordisk A/SNCT06323174CagriSema against placebo in type 2 diabetes on diet and exerciseWritten as CagrilintideReport a problem
- A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboCompletedPhase 2Novo Nordisk A/SNCT06131372CagriSema against each part on kidney damage in diabetesWritten as CagrilintideReport a problem
- A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietActive, not recruitingPhase 1Novo Nordisk A/SNCT07184086CagriSema against a low-energy diet on energy metabolismWritten as CagriSema (Cagrilintide B + semaglutide I)Report a problem
- A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyCompletedPhase 2Novo Nordisk A/SNCT06797869CagriSema against placebo for painful diabetic neuropathyWritten as CagriSema (Cagrilintide B and Semaglutide I)Report a problem
See all 50 studies that test cagrilintide →
Tested on its own · 19 — no other medicine in its arm
- A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and ObesityNot yet recruitingPhase 3Novo Nordisk A/SNCT07919405CagriSema against each part and placebo on blood pressureWritten as CagriSemaReport a problem
- Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse EventsRecruitingPhase 1Novo Nordisk A/SNCT07607587Against placebo in people who could not tolerate GLP-1 drugsWritten as CagrilintideReport a problem
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightRecruitingPhase 3Novo Nordisk A/SNCT07564414Two CagriSema doses against semaglutide for weight lossWritten as CagrisemaReport a problem
- Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaRecruitingPhase 3Novo Nordisk A/SNCT07817251Switching from semaglutide to CagriSema in type 2 diabetesWritten as CagriSemaReport a problem
- A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body WeightRecruitingPhase 3Novo Nordisk A/SNCT07745504Two cagrilintide pen versions against placebo for weight lossWritten as CagrilintideReport a problem
- A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or ObesityRecruitingPhase 1Novo Nordisk A/SNCT07597018Bioequivalence of two cagrilintide versionsWritten as Cagrilintide DReport a problem
- A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or ObesityRecruitingPhase 1Novo Nordisk A/SNCT07557953Its effect on food intake and appetiteWritten as CagrilintideReport a problem
- Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideActive, not recruitingPhase 3Novo Nordisk A/SNCT07220759Alone against placebo for weight loss in type 2 diabetesWritten as CagrilintideReport a problem
- A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightCompletedPhase 1Novo Nordisk A/SNCT07605052Blood levels of two cagrilintide versions comparedWritten as Cagrilintide BReport a problem
- Weight Loss in People Living With Overweight or Obesity Following Treatment With CagrilintideActive, not recruitingPhase 3Novo Nordisk A/SNCT07220642Alone against placebo for weight lossWritten as CagrilintideReport a problem
- A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 DiabetesWithdrawnPhase 2Novo Nordisk A/SNCT07357740Two CagriSema pen versions compared in type 2 diabetesWritten as CagriSemaReport a problem
- A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightWithdrawnPhase 3Novo Nordisk A/SNCT07357766Two CagriSema pen versions against placebo for weight lossWritten as CagrisemaReport a problem
- A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the BodyCompletedPhase 1Novo Nordisk A/SNCT05564104Blood levels with liver impairment, and its bioavailabilityWritten as CagrilintideReport a problem
- A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy ParticipantsCompletedPhase 1Novo Nordisk A/SNCT05804162Its effect on heart rhythm in healthy peopleWritten as CagrilintideReport a problem
- Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.CompletedPhase 2Novo Nordisk A/SNCT03856047Dose finding for weight loss against placebo and liraglutideWritten as NNC0174-0833Report a problem
- A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney FunctionCompletedPhase 1Novo Nordisk A/SNCT04209049Blood levels with impaired kidney functionWritten as NNC0174-0833Report a problem
- A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With ObesityCompletedPhase 1Novo Nordisk A/SNCT03787225Single doses in Japanese and Caucasian menWritten as NNC0174-0833Report a problem
- Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or OverweightCompletedPhase 1Novo Nordisk A/SNCT02958085Repeated doses in people with overweight or obesityWritten as NNC0174-0833Report a problem
- Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male SubjectsCompletedPhase 1Novo Nordisk A/SNCT02300844First single doses in healthy men of varied weightWritten as NNC0174-0833Report a problem
Tested with established drugs · 26 — they are given beside it
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesRecruitingPhase 3Novo Nordisk A/SNCT07282613CagriSema against placebo in young people with type 2 diabetesWritten as CagriSema (Cagrilintide B and Semaglutide I)Report a problem
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightRecruitingPhase 3Novo Nordisk A/SNCT07253285Alone or as CagriSema for weight loss in children and adolescentsWritten as CagrilintideReport a problem
- The Role of the Amylin Analogue Cagrilintide in Bone MetabolismRecruitingPhase 1Novo Nordisk A/SNCT07010432Alone, with semaglutide or as CagriSema on bone lossWritten as CagrilintideReport a problem
- Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)RecruitingPhase 1Novo Nordisk A/SNCT07527195Alone, with semaglutide or as CagriSema on muscle healthWritten as CagrilintideReport a problem
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorCompletedPhase 3Novo Nordisk A/SNCT06221969CagriSema against tirzepatide in type 2 diabetes on metforminWritten as CagrilintideReport a problem
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothCompletedPhase 3Novo Nordisk A/SNCT06534411Low-dose CagriSema against tirzepatide in type 2 diabetesWritten as CagrilintideReport a problem
- A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightActive, not recruitingPhase 3Novo Nordisk A/SNCT05567796CagriSema against each part and placebo for weight lossWritten as CagrilintideReport a problem
- A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termActive, not recruitingPhase 3Novo Nordisk A/SNCT07011667CagriSema for weight loss and long-term maintenanceWritten as CagriSema (Cagrilintide B and Semaglutide I)Report a problem
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseCompletedPhase 3Novo Nordisk A/SNCT06323174CagriSema against placebo in type 2 diabetes on diet and exerciseWritten as CagrilintideReport a problem
- A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboCompletedPhase 2Novo Nordisk A/SNCT06131372CagriSema against each part on kidney damage in diabetesWritten as CagrilintideReport a problem
- A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietActive, not recruitingPhase 1Novo Nordisk A/SNCT07184086CagriSema against a low-energy diet on energy metabolismWritten as CagriSema (Cagrilintide B + semaglutide I)Report a problem
- A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyCompletedPhase 2Novo Nordisk A/SNCT06797869CagriSema against placebo for painful diabetic neuropathyWritten as CagriSema (Cagrilintide B and Semaglutide I)Report a problem
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without MetforminCompletedPhase 3Novo Nordisk A/SNCT06323161CagriSema against placebo in type 2 diabetes on basal insulinWritten as CagrilintideReport a problem
- REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsActive, not recruitingPhase 3Novo Nordisk A/SNCT05669755CagriSema on heart attacks and strokes in heart diseaseWritten as CagrilintideReport a problem
- A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorCompletedPhase 3Novo Nordisk A/SNCT06065540CagriSema against each part in type 2 diabetes on metforminWritten as CagrilintideReport a problem
- A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose WeightCompletedPhase 3Novo Nordisk A/SNCT06388187Lower CagriSema doses against placebo for weight lossWritten as CagrilintideReport a problem
- Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 DiabetesCompletedPhase 1Novo Nordisk A/SNCT06403761CagriSema and each part on insulin sensitivity in type 2 diabetesWritten as CagrilintideReport a problem
- A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightCompletedPhase 3Novo Nordisk A/SNCT06131437CagriSema against tirzepatide for weight loss in obesityWritten as CagrilintideReport a problem
- A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose WeightCompletedPhase 3Novo Nordisk A/SNCT05394519CagriSema against placebo in type 2 diabetes with obesityWritten as CagrilintideReport a problem
- A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose WeightCompletedPhase 3Novo Nordisk A/SNCT05813925CagriSema against semaglutide for weight loss in East AsiaWritten as CagrilintideReport a problem
Showing 20 of 26. See all 26 →
Tested in a combination · 5 — another drug in the study is under test too
- A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or ObesityCompletedPhase 1Novo Nordisk A/SNCT06716307Two CagriSema pen versions compared for blood levelsWritten as CagriSema (cagrilintide B and semaglutide I)Report a problem
- A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body WeightCompletedPhase 1Novo Nordisk A/SNCT06289504How CagriSema changes atorvastatin and warfarin levelsWritten as CagrilintideReport a problem
- Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseCompletedPhase 2Novo Nordisk A/SNCT06409130Alone and in CagriSema on alcohol-related liver diseaseWritten as Cagrilintide + semaglutideReport a problem
- A Study of How CagriSema Works on Appetite in People With Excess Body WeightCompletedPhase 1Novo Nordisk A/SNCT06267092CagriSema on appetite and brain activity in overweightWritten as Cagrilintide and SemaglutideReport a problem
- A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or ObesityCompletedPhase 1Novo Nordisk A/SNCT04940078Given with semaglutide in one injection or twoWritten as CagrilintideReport a problem
Beside a new treatment under test · 1 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with cagrilintide: Gastric Inhibitory Polypeptide 1
As the comparator · 1 — what is tested is compared with cagrilintide
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call cagrilintide · ClinicalTrials.gg INT001638
- MeSH (NLM) C000717792cagrilintideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) AO43BIF1U8CAGRILINTIDEConfirmed FDA, NLM
- NCI Thesaurus C175752CagrilintideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000717792 | cagrilintide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | AO43BIF1U8 | CAGRILINTIDE | Confirmed FDA, NLM |
| NCI Thesaurus | C175752 | Cagrilintide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.